Evidence map›Paper›PMID 39208520›Full record

Trial reportSleep medicine2024

Impact of a ketogenic diet on sleep quality in people with relapsing multiple sclerosis.

Jacob Perlman, Emma Wetmore, Diana Lehner-Gulotta, Brenda Banwell, A G Christina Bergqvist, Rachael Coleman, Shanshan Chen, Mark Conaway, Myla D Goldman, Anne Marie Morse and 1 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Sleep medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03718247 (The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03718247 completednot on this map

The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis

TypeobservationalSponsorUniversity of VirginiaRan2018 to 2021Enrolled45ConditionsRelapsing Remitting Multiple SclerosisArmsModified Atkins diet
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jacob PerlmanDept of Neurology, University of Virginia, Charlottesville VA, USA.
Emma WetmoreDept of Neurology, University of Virginia, Charlottesville VA, USA; School of Medicine, Medical University of South Carolina, Charleston SC, USA.
Diana Lehner-GulottaDivision of Child Neurology, Dept. of Neurology, University of Virginia, Charlottesville, VA, USA.
Brenda BanwellDivision of Child Neurology, Children's Hospital of Philadelphia, Dept. of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
A G Christina BergqvistDivision of Child Neurology, Children's Hospital of Philadelphia, Dept. of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Rachael ColemanDept of Neurology, University of Virginia, Charlottesville VA, USA.
Shanshan ChenDept of Public Health Sciences, Virginia Commonwealth University, Richmond VA, USA.
Mark ConawayDept of Public Health Sciences, University of Virginia, Charlottesville VA, USA.
Myla D GoldmanDept of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
Anne Marie MorseDivision of Child Neurology and Pediatric Sleep Medicine, Geisinger Medical Center/Janet Weis Children's Hospital, Danville, PA, USA.
J Nicholas BrentonDivision of Child Neurology, Dept. of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: jnb8h@uvahealth.org.

Funding

The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, JOHNSTON, KAREN C. · 2019 to 2023
$20.3M
Institutional Career Development CoreKL2TR003016 · NCATS · UNIVERSITY OF VIRGINIA · PI PAPIN, JASON, WORRALL, BRADFORD B · 2019 to 2023
$3.9M
Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple SclerosisK23NS116225 · NINDS · UNIVERSITY OF VIRGINIA · PI BRENTON, JAMES NICHOLAS · 2021 to 2025
$962k
NCATS NIH HHS KL2 TR003016NCATS NIH HHS UL1 TR003015NINDS NIH HHS K23 NS116225
6 · The paper itself

Abstract

backgroundSleep disturbance in MS is common and can significantly impair overall quality of life. The ketogenic diet (KD) associates with improved sleep quality in people living with epilepsy and may have similar benefits when used within MS; however, the impact of a KD on sleep in this population remains poorly defined.

methodsForty-five patients with relapsing MS enrolled into a 6-month KD intervention trial and completed self-reported assessments of sleep quality and sleep disorder symptoms prior to diet initiation and while on diet, using the Epworth Sleepiness Scale (ESS) and Sleep Disorders Symptom Checklist-25 (SDS). Participants who did not complete sleep assessments at baseline and 6-months were excluded from analysis. In addition to sleep metrics, data collection included anthropometrics and MS-related fatigue scores.

resultsThirty-nine of 45 (87 %) participants completed the required sleep assessments. There was a mean reduction in ESS score of 1.90 (95 % CI [-2.85, -0.94], p < 0.001). Total SDS score decreased at 6-months on KD (-4.4, 95 % CI [-7.1, -1.7], p = 0.002), with improvements noted in insomnia (-1.55, 95 % CI [-2.66, -0.43], p = 0.008), obstructive sleep apnea (-0.91, 95 % CI [-1.57, -0.25], p = 0.008), and restless leg syndrome screening scores (-1.00, 95 % CI [-1.95, -0.051], p = 0.04). Sleep duration was unchanged on KD.

conclusionKD associates with improvements in daytime sleepiness, independent of sleep duration, and common comorbid sleep disorders in people living with relapsing MS. The findings herein support the benefits of KD on sleep quality and highlight the potential role of dietary therapeutics for sleep disorders in neurological disease. TRIAL REGISTRATION INFORMATION: Registered on Clinicaltrials.gov under registration number NCT03718247, posted on Oct 24, 2018. First patient enrollment date: Nov 1, 2018. Link: https://clinicaltrials.gov/ct2/show/NCT03718247?term=NCT03718247&draw=2&rank=1.

Indexed as

Diet, KetogenicMultiple Sclerosis, Relapsing-RemittingSleep QualityAdultFemaleHumansMaleMiddle AgedQuality of LifeSelf ReportSleep Wake DisordersApneaDietInsomniaObesityRestless legSleep

Identifiers

PMID39208520
PMCPMC11393576

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.